Business
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m. ET – SAN JOSE, Calif.,
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS –\n– Conference call to commence at 6:30 p.m. ET –\nSAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium (\"SABCS\"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.\n\n \n \n \n \n \n \n\n \nAnixa is pleased to invite all interested parties to participate in a conference call today at 6:30 p.m. ET, during which the new data will be discussed.\nConference Call Details:\nPresentation host: \nAnixa management, with special guest speakers (bios below)\nDate and time: \nToday, December 6, 2023, at 6:30 p.m. ET\nPhone access: \nRegistration Link to receive your dial-in number and unique PIN\nWebcast: \nAvailable at www.anixa.com under \"Events & Presentations\"\nGuest Speakers:\nJennifer Davis: Ms. Davis is a nurse, wife, mother of three, and Triple Negative Breast Cancer survivor. She was diagnosed in 2018 and had chemotherapy, radiation, a double mastectomy, and was the first person in the world to receive Anixa's breast cancer vaccine in 2021 through Cleveland Clinic. Ms. Davis is passionate about preventing breast cancer for herself and all women.H. Michael Shepard, PH.D.: Dr. Shepard is a Key Opinion Leader in oncology. He has made seminal contributions to the fields of immunotherapy, gene therapy of cancer, and precision medicine. Dr. Shepard is best known as the inventor of the life-saving breast cancer drug Herceptin® (trastuzumab). Herceptin was the first monoclonal antibody therapy approved for cancer, and it spawned an explosion in monoclonal therapies and antibody-drug conjugates for cancer. Herceptin still generates sales of over $5 billion per year and is one of the best-selling cancer drugs of all time, having been prescribed for over 2.3 million breast cancer sufferers. Among his many awards and honors are the Warren Alpert Foundation Prize from Harvard Medical School and the Lasker-Debakey Award. The Alpert Awa...